Infinitopes launches first-in-human trial of vaccine targeting oesophageal cancer - Pharmafile

Infinitopes launches first-in-human trial of vaccine targeting oesophageal cancer - Pharmafile

The cancer biotech company Infinitopes has gained approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate its ITOP1 vaccine targeting oesophageal cancer. This marks the first ever trial to administer a cancer vaccine in a neoadjuvant setting while the primary tumour remains. With Clinical Trial Application (CTA) approval, the upcoming phase […] The post Infinitopes launches first-in-human trial of vaccine target…

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer – Optimum Strategic CommunicationsLink to: Xeltis successfully passes evaluation phase for €10million investment fro

Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]